(Press-News.org) Two studies from Johns Hopkins Kimmel Cancer Center researchers add to preliminary evidence that high-dose radiation treatment, called stereotactic body radiotherapy, appears to be safe and as effective as standard radiation treatment for certain patients with pancreatic cancer whose tumors are advanced but have not spread.
The studies also suggest, the researchers say, that stereotactic body radiotherapy (SBRT) may have some advantages over traditional radiation for some patients, because doses can be delivered over the course of one week, unlike six or seven weeks with standard radiation therapy. Some patients also reported significantly less pain and no significant decrease in their quality of life after SBRT, the scientists found.
Overall, the two studies show that SBRT for locally advanced pancreatic cancer "appears to be at least as good as standard radiation, and in some cases, it appears to be better," says Joseph Herman, M.D., M.Sc., co-director of the Johns Hopkins Pancreatic Cancer Multidisciplinary Clinic. He cautioned, however, that the results need to be confirmed in randomized trials.
Conventional or standard radiation is delivered in relatively low doses, usually daily over the course of several weeks. SBRT uses a higher dose of carefully targeted radiation to treat tumors, delivered all at once or in a few "fractionated" doses.
The researchers report that patients experienced minimal gastrointestinal side effects, such as ulcers and intestinal inflammation, when SBRT is delivered in five separate, fractionated doses, rather than one large dose. In one prospective, multicenter study of 49 patients who received the five doses, five patients developed one of these toxic side effects, compared to nine of 16 patients (47 percent) of those who received the one-dose SBRT regiment in a previous study.
In some cases, patients were able to have their tumors surgically removed with few or no cancer cells left behind, says Herman. Before treatment with chemotherapy and SBRT, these patients were thought to have tumors unsuitable for surgery.
"The majority of patients we treat with stereotactic radiation have tumors that cannot be safely or effectively removed by surgery, and therefore their average survival is only about a year," Herman says. "So if five days of stereotactic radiation has outcomes equivalent to the six weeks of standard chemotherapy and radiation, then patients can spend less time receiving treatment and more time at home with their families."
Herman says that the shorter treatment duration with SBRT could also give patients quicker access to full-dose chemotherapy. The long duration of standard radiation may delay full-dose chemotherapy, potentially giving cancers more time to spread.
The study published April 1 in the journal Cancer by Herman and his colleagues, included 49 patients with locally advanced pancreatic cancer treated at The Johns Hopkins Hospital, Stanford University, and Memorial Sloan Kettering Cancer Center. The patients received SBRT in five fractionated doses, and chemotherapy with gemcitabine before and after the radiotherapy.
Four weeks after SBRT, all 22 patients who completed a quality of life questionnaire reported an eight point reduction in pain from a baseline measure of 25, and their quality of life stayed the same, which Herman says is encouraging.
In a second study, published January 2015 in the Annals of Surgical Oncology, Herman and his colleagues analyzed information on patients with pancreatic cancer who received SBRT and chemotherapeutic drugs at The Johns Hopkins Hospital between 2010 and 2014. Of 88 patients, eight experienced severe gastrointestinal side effects, and 19 with tumors previously considered inoperable were able to have surgery after SBRT.
Pancreatic tumors can cling and grow around blood vessels, making them especially difficult to remove. "After we irradiate it with SBRT, the tumor changes to a form that can be more easily pried away from the vessel," Herman says.
SBRT isn't for all patients with pancreatic cancer, he warns. People who have tumors larger than 8 centimeters in diameter or a little over 3 inches, or have a tumor that is invading the area of the bowel or the stomach, usually can't get SBRT because of the risk to normal tissues.
Herman says he plans to work with other clinicians and scientists to test combinations of SBRT with therapies that help the immune system fight cancer more effectively, such as a Johns Hopkins-developed experimental pancreatic cancer vaccine.
INFORMATION:
Other Johns Hopkins scientists who contributed to the Annals of Surgical Oncology study include Shalini Moningi, Avani S. Dholakia, Siva P. Raman, Amanda Blackford, John L. Cameron, Dung T. Le, Ana M.C. De Jesus-Acosta, Amy Hacker-Prietz, Lauren M. Rosati, Ryan K. Assadi, Shirl Dipasquale, Timothy M. Pawlik, Lei Zheng, Matthew J. Weiss, Daniel A. Laheru and Christopher L. Wolfgang.
Other scientists on the Cancer study include Daniel T. Chang, Jonathan S. Pai, George A. Fisher, Laurie A. Columbo and Albert C. Koong of the Stanford University School of Medicine; Karyn A. Goodman and Eileen O'Reilly of Memorial Sloan Kettering Cancer Center; and Johns Hopkins researchers Avani S. Dholakia, Siva P. Raman, Amy Hacker-Prietz, Christine A. Iacobuzio-Donahue, Mary E. Griffith, Timothy M. Pawlik, Jonathan S. Pai, Aaron T. Wild, Lauren M. Rosati, Lei Zheng, Christopher L. Wolfgang, Daniel A. Laheru and Elizabeth A. Sugar.
Funding for the studies was provided by the Claudio X. Gonzalez Family Foundation, the Flannery Family Foundation, the Alexander Family Foundation, the Keeling Family Foundation, the DeSanti Family Foundation, the McKnight Family, the My Blue Dots Foundation and the Viragh Family Foundation Inc.
On the Web:
Cancer: http://onlinelibrary.wiley.com/doi/10.1002/cncr.29161/abstract
Annals of Surgical Oncology: http://www.annsurgoncol.org/journals/abstract.html?v=0&j=10434&i=-1&a=4274_10.1245_s10434-014-4274-5&doi=
Media Contacts:
Vanessa Wasta, 410-614-2916, wasta@jhmi.edu
Amy Mone, 410-614-2915, amone@jhmi.edu
Changing the size of cell-carrying spheres may surmount the difficulties that have bedeviled diabetes researchers trying to ferry insulin-producing islet cells into hosts as a way to treat type 1 diabetes.
New findings published in the journal Nature Materials suggest that for the spherical capsules, bigger may be better.
Tiny gel capsules carrying islet cells allow insulin to seep out, and nutrients to get in, through microscopic holes. The holes are small enough, however, to isolate and protect the encapsulated cells from the cells of host's immune system, which would ...
CORVALLIS, Ore. -- Researchers at Oregon State University are pursuing a new concept in treatment of epithelial cancer, especially head and neck cancer, by using two promising "analogs" of an old compound that was once studied as a potent anti-tumor agent, but long ago abandoned because it was too toxic.
The analogs are more highly selective than the parent compound, pactamycin, which originally was found to kill all cells, from bacteria to mammals, by inhibiting their protein synthesis.
The pactamycin analogs, which were developed with biosynthetic engineering, also ...
Largest study of its type shows people associate science with men in all 66 nations studied
Dominance of men in science stereotypes strongest in Scandinavian countries, especially the Netherlands
Gender-science stereotypes weaker in nations with more female scientists
Interactive table providing comprehensive rankings for all 66 nations
EVANSTON, Ill. --- The Netherlands had the strongest stereotypes associating science with men more than women, according to a new Northwestern University study that included data from nearly 350,000 people in 66 nations.
These ...
Jumping spiders were already known to see in remarkably high resolution, especially considering that their bodies are less than a centimeter long. Now, researchers reporting in the Cell Press journal Current Biology on May 18 have figured out how spiders in the colorful genus Habronattus see in three color "channels," as most humans do.
"The eyes of jumping spiders could not be more different from those of butterflies or birds, and yet all three tune the color sensitivities using pigments that filter light," says Nathan Morehouse of the University of Pittsburgh. "It's ...
Researchers have uncovered the first geologic evidence that New Zealand's southern Hikurangi margin can rupture during large earthquakes. The two earthquakes took place within the last 1000 years, and one was accompanied by a tsunami, according to the study published in the Bulletin of the Seimological Society of America (BSSA).
The earthquakes took place roughly 350 years apart, according to the analysis by Kate Clark of GNS Science and colleagues. This may mean that the time between large earthquakes in this region is shorter than scientists have thought. The current ...
In a first-of-its-kind clinical trial, physician-scientists at University Hospitals (UH) Case Medical Center Seidman Cancer Center and Case Western Reserve University School of Medicine found that a new non-invasive technology for colon cancer screening is a promising alternative to colonoscopy for African Americans. The study recruited patients to compare the effectiveness of stool DNA (sDNA) testing with colonoscopy for detecting large colon polyps.
SDNA is a test that detects colon cancer in its earliest stages, based on analysis of stool DNA. Developed in the laboratory ...
(Philadelphia, PA) - Today's academic medical centers (AMCs) need to embrace the changing healthcare marketplace or run the risk of becoming the next Kodak - a former industrial giant that became obsolete when it failed to adapt to a shifting technological landscape.
That is the premise of a commentary published this month electronically ahead of the print edition of Academic Medicine, the journal of the Association of American Medical Colleges. The commentary is authored by Verdi DiSesa, MD, MBA, Chief Operating Officer of the Temple University Health System (TUHS) and ...
PHILADELPHIA - An important link between the human body clock and the immune system has relevance for better understanding inflammatory and infectious diseases, discovered collaborators at the Perelman School of Medicine at the University of Pennsylvania and Trinity College, Dublin. In a study published this week in the Proceedings of the National Academy of Sciences, they report how a critical white blood cell called the macrophage, when exposed to bacteria, makes the biological clock inside the macrophage stop, allowing it to become inflamed.
The complex mechanism they ...
ATS 2015, DENVER - Patients undergoing percutaneous coronary intervention (PCI), a coronary artery widening procedureused to treat heart disease, are at high risk for obstructive sleep apnea (OSA), according to new research presented at the 2015 American Thoracic Society International Conference.
"Our findings, in a large, multicenter sample of patients, reinforce the known association between OSA and cardiovascular disease," said researcher Luciano Drager, MD, PhD, of the University of São Paulo School of Medicine in Brazil. "Nearly half of the patients in our ...
Researchers have found that adding genetic information to a former or current smoker's clinical risk profile results in a reclassification of their risk for lung cancer in about one in four patients. Preliminary findings from their lung cancer screening feasibility study also suggests that those whose genetic and clinical risk placed them in the highest risk category were more likely to adhere to follow-up computed tomography (CT) scans during screening.
The results of this study, conducted at El Camino Hospital in Mountain View, CA, follows on the heels of the National ...
